A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)

PURPOSE: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. METHODS: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. RESULTS: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0-I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. CONCLUSION: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-20
DOI
https://doi.org/10.1158/1078-0432.ccr-26-0501
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)

Andrew David Redfern, Janine Margaret Lombard, Sherene Loi, Rebecca Asher et al.
1 links
Clinical Cancer Research
Breast Cancer Treatment Studies
article

A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)

Andrew David Redfern, Janine Margaret Lombard, Sherene Loi, Rebecca Asher, Nicholas Zdenkowski, Val Gebski, Benjamin Frederik Dessauvagie, Clair Shadbolt, Prudence A. Francis, Cameron Edward Snell, Luis E. Lara Gonzalez, Nicholas Wilcken, Courtney T. van Geelen, Frances M. Boyle, Wendy A. Raymond, Núria Chic, Franco Caramia, Andrew John Spillane, J. Kay, Nicholas Murray, Heath Badger, Susan Tiley
article en

Abstract

PURPOSE: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. METHODS: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. RESULTS: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0-I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. CONCLUSION: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.

Clinical Cancer Research
The University of Sydney (AU), Royal Adelaide Hospital (AU), The University of Western Australia (AU), Peter MacCallum Cancer Centre (AU), Fiona Stanley Hospital (AU), Gosford Hospital (AU), Flinders Medical Centre (AU), Westmead Hospital (AU), Breast Cancer Trials (AU), St Vincent’s Private Hospital Sydney (AU), Calvary Mater Newcastle Hospital (AU), University of Newcastle Australia (AU)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon